vs
Esperion Therapeutics, Inc.（ESPR）与RENASANT CORP（RNST）财务数据对比。点击上方公司名可切换其他公司
RENASANT CORP的季度营收约是Esperion Therapeutics, Inc.的1.6倍（$273.8M vs $168.4M），过去两年RENASANT CORP的营收复合增速更高（29.3% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
瑞耐桑特银行是美国密西西比州图珀洛的区域商业金融机构，母公司为瑞耐桑特公司，在阿拉巴马、佛罗里达、佐治亚、密西西比、路易斯安那、田纳西、北卡罗来纳、南卡罗来纳八州拥有280多家分支机构，旗下还运营内容平台“瑞耐桑特国度”，发布博客及节目内容。
ESPR vs RNST — 直观对比
营收规模更大
RNST
是对方的1.6倍
$168.4M
两年增速更快
RNST
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $273.8M |
| 净利润 | — | $88.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | 32.2% |
| 营收同比 | 143.7% | — |
| 净利润同比 | — | 112.5% |
| 每股收益（稀释后） | $0.32 | $0.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRRNST
| Q1 26 | — | $273.8M | ||
| Q4 25 | $168.4M | $278.4M | ||
| Q3 25 | $87.3M | $269.5M | ||
| Q2 25 | $82.4M | $267.2M | ||
| Q1 25 | $65.0M | $170.7M | ||
| Q4 24 | $69.1M | $167.1M | ||
| Q3 24 | $51.6M | $220.3M | ||
| Q2 24 | $73.8M | $163.8M |
净利润ESPRRNST
| Q1 26 | — | $88.2M | ||
| Q4 25 | — | $78.9M | ||
| Q3 25 | $-31.3M | $59.8M | ||
| Q2 25 | $-12.7M | $1.0M | ||
| Q1 25 | $-40.5M | $41.5M | ||
| Q4 24 | — | $44.7M | ||
| Q3 24 | $-29.5M | $72.5M | ||
| Q2 24 | $-61.9M | $38.8M |
营业利润率ESPRRNST
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 34.8% | ||
| Q3 25 | -11.4% | 27.9% | ||
| Q2 25 | 8.6% | 1.0% | ||
| Q1 25 | -34.0% | 30.4% | ||
| Q4 24 | -6.4% | 29.8% | ||
| Q3 24 | -31.0% | 44.2% | ||
| Q2 24 | 3.5% | 29.6% |
净利率ESPRRNST
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 28.4% | ||
| Q3 25 | -35.9% | 22.2% | ||
| Q2 25 | -15.4% | 0.4% | ||
| Q1 25 | -62.2% | 24.3% | ||
| Q4 24 | — | 26.8% | ||
| Q3 24 | -57.2% | 32.9% | ||
| Q2 24 | -83.9% | 23.7% |
每股收益（稀释后）ESPRRNST
| Q1 26 | — | $0.94 | ||
| Q4 25 | $0.32 | $0.78 | ||
| Q3 25 | $-0.16 | $0.63 | ||
| Q2 25 | $-0.06 | $0.01 | ||
| Q1 25 | $-0.21 | $0.65 | ||
| Q4 24 | $-0.14 | $0.70 | ||
| Q3 24 | $-0.15 | $1.18 | ||
| Q2 24 | $-0.33 | $0.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $1.2B |
| 总债务越低越好 | — | $806.2M |
| 股东权益账面价值 | $-302.0M | $3.9B |
| 总资产 | $465.9M | $27.1B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资ESPRRNST
| Q1 26 | — | $1.2B | ||
| Q4 25 | $167.9M | $1.1B | ||
| Q3 25 | $92.4M | $1.1B | ||
| Q2 25 | $86.1M | $1.4B | ||
| Q1 25 | $114.6M | $1.1B | ||
| Q4 24 | $144.8M | $1.1B | ||
| Q3 24 | $144.7M | $1.3B | ||
| Q2 24 | $189.3M | $851.9M |
总债务ESPRRNST
| Q1 26 | — | $806.2M | ||
| Q4 25 | — | $499.8M | ||
| Q3 25 | — | $558.9M | ||
| Q2 25 | — | $557.0M | ||
| Q1 25 | — | $433.3M | ||
| Q4 24 | — | $430.6M | ||
| Q3 24 | — | $433.2M | ||
| Q2 24 | — | $428.7M |
股东权益ESPRRNST
| Q1 26 | — | $3.9B | ||
| Q4 25 | $-302.0M | $3.9B | ||
| Q3 25 | $-451.4M | $3.8B | ||
| Q2 25 | $-433.5M | $3.8B | ||
| Q1 25 | $-426.2M | $2.7B | ||
| Q4 24 | $-388.7M | $2.7B | ||
| Q3 24 | $-370.2M | $2.7B | ||
| Q2 24 | $-344.2M | $2.4B |
总资产ESPRRNST
| Q1 26 | — | $27.1B | ||
| Q4 25 | $465.9M | $26.8B | ||
| Q3 25 | $364.0M | $26.7B | ||
| Q2 25 | $347.1M | $26.6B | ||
| Q1 25 | $324.0M | $18.3B | ||
| Q4 24 | $343.8M | $18.0B | ||
| Q3 24 | $314.1M | $18.0B | ||
| Q2 24 | $352.3M | $17.5B |
负债/权益比ESPRRNST
| Q1 26 | — | 0.21× | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRRNST
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $271.5M | ||
| Q3 25 | $-4.3M | $135.5M | ||
| Q2 25 | $-31.4M | $-77.3M | ||
| Q1 25 | $-22.6M | $106.2M | ||
| Q4 24 | $-35.0M | $106.4M | ||
| Q3 24 | $-35.3M | $-1.7M | ||
| Q2 24 | $-7.2M | $-49.1M |
自由现金流ESPRRNST
| Q1 26 | — | — | ||
| Q4 25 | — | $237.8M | ||
| Q3 25 | — | $120.1M | ||
| Q2 25 | — | $-87.5M | ||
| Q1 25 | — | $101.3M | ||
| Q4 24 | — | $92.8M | ||
| Q3 24 | $-35.5M | $-5.3M | ||
| Q2 24 | $-7.3M | $-52.6M |
自由现金流率ESPRRNST
| Q1 26 | — | — | ||
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 44.6% | ||
| Q2 25 | — | -32.7% | ||
| Q1 25 | — | 59.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | -68.7% | -2.4% | ||
| Q2 24 | -9.9% | -32.1% |
资本支出强度ESPRRNST
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 12.1% | ||
| Q3 25 | 0.0% | 5.7% | ||
| Q2 25 | 0.0% | 3.8% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 8.2% | ||
| Q3 24 | 0.3% | 1.6% | ||
| Q2 24 | 0.1% | 2.1% |
现金转化率ESPRRNST
| Q1 26 | — | — | ||
| Q4 25 | — | 3.44× | ||
| Q3 25 | — | 2.27× | ||
| Q2 25 | — | -75.92× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | -0.02× | ||
| Q2 24 | — | -1.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RNST
| Net Interest Income | $223.6M | 82% |
| Noninterest Income | $50.3M | 18% |
